IDEAYA Biosciences (IDYA) Competitors

IDEAYA Biosciences (NASDAQ:IDYA) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations.

Do insiders & institutionals have more ownership in IDYA or BPMC?

98.3% of IDEAYA Biosciences shares are owned by institutional investors. 2.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate IDYA or BPMC?

IDEAYA Biosciences presently has a consensus price target of $54.27, suggesting a potential upside of 204.56%. Blueprint Medicines has a consensus price target of $126.56, suggesting a potential upside of 24.46%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe IDEAYA Biosciences is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Blueprint Medicines	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83

Does the MarketBeat Community prefer IDYA or BPMC?

Blueprint Medicines received 412 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. However, 71.72% of users gave IDEAYA Biosciences an outperform vote while only 68.23% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
IDEAYA Biosciences	Outperform Votes 142 71.72%	Underperform Votes 56 28.28%
Blueprint Medicines	Outperform Votes 554 68.23%	Underperform Votes 258 31.77%

Which has stronger earnings & valuation, IDYA or BPMC?

Blueprint Medicines has higher revenue and earnings than IDEAYA Biosciences. Blueprint Medicines is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$7M	222.96	-$274.48M	-$3.59	-4.96
Blueprint Medicines	$562.12M	11.68	-$67.09M	-$2.47	-41.17

Does the media prefer IDYA or BPMC?

In the previous week, IDEAYA Biosciences had 8 more articles in the media than Blueprint Medicines. MarketBeat recorded 24 mentions for IDEAYA Biosciences and 16 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.49 beat IDEAYA Biosciences' score of 1.08 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	14 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	15 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is IDYA or BPMC more profitable?

IDEAYA Biosciences has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. IDEAYA Biosciences' return on equity of -26.74% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-26.74%	-25.54%
Blueprint Medicines	-13.19%	-77.49%	-20.84%

Which has more volatility and risk, IDYA or BPMC?

IDEAYA Biosciences has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

IDEAYA Biosciences and Blueprint Medicines tied by winning 9 of the 18 factors compared between the two stocks.